Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SPDR S&P Pharmaceuticals ETF (NY:XPH)

47.06 -0.31 (-0.65%)
Streaming Delayed Price Updated: 12:12 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,026
Open 46.90
Bid (Size) 47.01 (2)
Ask (Size) 47.14 (18)
Prev. Close 47.37
Today's Range 46.90 - 47.23
52wk Range 35.22 - 49.31
Shares Outstanding 36,002
Dividend Yield 0.88%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade

Performance

YTD
+10.4%
+10.4%
1 Month
+2.3%
+2.3%
3 Month
+10.3%
+10.3%
6 Month
+23.0%
+23.0%
1 Year
+2.9%
+2.9%

More News

Read More
Pharma Tariffs Back In Spotlight On New Trump Threat
Via Investor's Business Daily
Topics ETFs Government World Trade
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Via Benzinga
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Via Benzinga
Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)
Via MarketMinute
Topics ETFs Economy
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Via Benzinga
Topics Government World Trade
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Via Benzinga
Topics Government World Trade
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Via Benzinga
Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe
Via Benzinga
Topics Government World Trade
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work
Via Investor's Business Daily
Topics ETFs Government
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Via Benzinga
Topics Government
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Via Benzinga
Topics ETFs Government
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Via Stocktwits
Topics Government Intellectual Property Lawsuit
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Via Benzinga
Topics ETFs
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?
Via Benzinga
Topics World Trade
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
Via Stocktwits
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4
Via Stocktwits
Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027
Via Benzinga
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Via Benzinga
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
Via Stocktwits
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
Via MarketBeat
Topics ETFs
Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
Via Benzinga
Topics Bankruptcy Lawsuit

Frequently Asked Questions

Is SPDR S&P Pharmaceuticals ETF publicly traded?
Yes, SPDR S&P Pharmaceuticals ETF is publicly traded.
What exchange does SPDR S&P Pharmaceuticals ETF trade on?
SPDR S&P Pharmaceuticals ETF trades on the New York Stock Exchange
What is the ticker symbol for SPDR S&P Pharmaceuticals ETF?
The ticker symbol for SPDR S&P Pharmaceuticals ETF is XPH on the New York Stock Exchange
What is the current price of SPDR S&P Pharmaceuticals ETF?
The current price of SPDR S&P Pharmaceuticals ETF is 47.06
When was SPDR S&P Pharmaceuticals ETF last traded?
The last trade of SPDR S&P Pharmaceuticals ETF was at 10/14/25 12:12 PM ET
What is the market capitalization of SPDR S&P Pharmaceuticals ETF?
The market capitalization of SPDR S&P Pharmaceuticals ETF is 1.69M
How many shares of SPDR S&P Pharmaceuticals ETF are outstanding?
SPDR S&P Pharmaceuticals ETF has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.